![]() |
市場調查報告書
商品編碼
2026910
女性用健康護理設備市場預測至2034年—按產品類型、類別、應用、最終用戶和地區分類的全球分析Women's Health Devices Market Forecasts to 2034 - Global Analysis By Product (Labor & Delivery, Critical Care, Contraceptives, Surgical, Diagnostics and Other Products), Type, Application, End User and By Geography |
||||||
根據 Stratistics MRC 的數據,預計到 2026 年,全球女性醫療設備市場規模將達到 722 億美元,並在預測期內以 11.3% 的複合年成長率成長,到 2034 年將達到 1704 億美元。
與不孕症治療、計劃生育以及孕產婦和月經健康相關的產品被歸類為女性用醫療保健器材。這些器械涵蓋了種類繁多的醫療設備,專門用於治療女性特有的疾病和健康問題。它們能夠解決許多女性健康問題,包括更年期、懷孕、分娩和生殖健康。此外,它們還能用於治療乳癌、子宮頸癌和骨盆底功能障礙等疾病。
根據國際癌症研究機構(IARC)的數據,乳癌已超過肺癌,成為女性最常見的癌症類型。 2020年,全球約有230萬例新增乳癌病例。此外,2020年全球約有920萬例新增癌症病例和440萬例女性癌症相關死亡病例。
人們對女性健康的認知和關注度不斷提高
人們對女性健康問題的日益關注以及相關的維權活動正在推動針對特定醫療需求的智慧型設備的研發。公共衛生和教育措施也增加了對這些設備的需求。女性可以使用這些設備追蹤自身健康指標的變化,這些指標通常強調預防性健康措施,並鼓勵早期療育和預防活動。這些因素正在推動市場擴張。
市場滲透率不足
儘管對女性健康設備的需求極為重要且不斷成長,但與已開發國家相比,新興地區大眾對許多女性健康問題的認知仍然較低。人們對影響女性健康的各種疾病的徵兆普遍缺乏了解,而這些疾病本可以透過適當的診斷和治療工具輕鬆治療或解決。這顯著降低了這些國家女性的存活率。因此,這一因素可能會阻礙市場擴張。
該疾病盛行率不斷上升
由於診斷技術的進步和公眾意識的提高等多種因素,預防醫學的普及導致過去幾十年女性健康問題的總體發病率顯著上升。這種發病率的顯著成長意味著,現在有相當數量的患者患有慢性病或嚴重,這些疾病不僅對她們的日常生活產生負面影響,而且顯著增加了她們的死亡風險。這些因素正在影響市場擴張。
維修成本高且結構複雜
這些設備需要昂貴的定期維護和維修。對專業技術人員和零件的需求會推高成本。在需要檢查和維護期間,設備可能無法使用,這可能會影響已安排的預約和醫療保健服務。有些設備結構複雜精密,維護難度高。這種複雜性也會延長維修時間。因此,這一因素可能會阻礙市場成長。
新冠疫情導致業界主要企業的收入下降。疫情期間,包括排卵監測儀、子宮內避孕器(IUD)、月經緩解產品和女性用保險套在內的女性用避孕產品需求下降。由於消費者出行受限和嚴格的社交距離措施減少了人際互動,女性用避孕產品的銷售量也隨之下降。
在預測期內,慢性病細分市場預計將成為最大的細分市場。
在預測期內,慢性病細分市場預計將成為最大的組成部分。飲食習慣的改變、缺乏運動以及生活方式的改變,導致女性慢性病(包括糖尿病、癌症、心臟病和其他疾病)的盛行率不斷上升。癌症是女性最常見的慢性病。隨著肺癌、卵巢癌、大腸直腸癌和乳癌在女性中發病率的不斷上升,這一細分市場正呈現顯著成長。
在預測期內,醫院和診所領域預計將呈現最高的複合年成長率。
在預測期內,醫院和診所板塊預計將呈現最高的複合年成長率。這可能是由於越來越多的人傾向於選擇醫院治療大多數疾病。該板塊成長的主要促進因素包括公立和私立醫院使用率的提高、私立診所的擴張、醫院設立女性專用病房以及醫院診斷和治療基礎設施的加強和發展。
由於北美擁有龐大的女性人口,預計該地區將在預測期內佔據最大的市場佔有率。女性醫療保健方面的巨額支出以及由此產生的對高科技設備的高需求,預計將進一步鞏固該地區的市場主導地位。該地區的主要市場參與者預計將繼續增加研發、臨床試驗和創新醫療設備引進的投入,這將進一步刺激市場需求。
預計亞太地區在預測期內將維持最高的複合年成長率。由於各國政府加強促進性別平等,該地區女性人口正快速成長。此外,女性勞動參與率的提高也增加了女性的可支配所得。女性族群中各種慢性疾病(如癌症、糖尿病、心血管疾病和呼吸系統疾病)盛行率的上升預計將推動市場成長。
According to Stratistics MRC, the Global Women's Health Devices Market is accounted for $72.2 billion in 2026 and is expected to reach $170.4 billion by 2034 growing at a CAGR of 11.3% during the forecast period. Products for fertility, family planning, and maternal and menstrual health are classified as women's health gadgets. These gadgets include a broad variety of medical equipment made especially to treat illnesses or health problems that are exclusive to women. These devices address a number of women's health issues, including menopause, pregnancy, delivery, and reproductive health. They also address illnesses including breast and cervical cancer, pelvic floor problems, and more.
According to the International Agency for Research on Cancer, the female breast cancer has become the most diagnosed type of cancer by surpassing the lungs cancer. Around 2.3 million new cases of breast cancer were reported in 2020. Around 9.2 million new cases of cancer and 4.4 million cancer deaths in female were reported in 2020.
Rising awareness and focus on women's health
The creation of gadgets that meet particular medical demands has been aided by increased awareness of women's health concerns and activities cantered around them. The need for these gadgets has also grown as a result of public health initiatives and educational initiatives. Women may follow changes in their health markers using these gadgets, which generally highlight preventative health measures and encourage early intervention and preventive activities. These are the aspects fostering the market's expansion.
Lack of market penetration
Despite a crucial and increasing demand for women's health equipment, awareness of many women's diseases is poor among the general public in emerging regions, as opposed to industrialized countries. A great deal of knowledge is lacking on the many signs of disorders affecting women's health that are readily treated or resolved with the right diagnosis and treatment tools. These seriously impair women's survival rates in these nations. Therefore, this factor might impede market expansion.
Rise in prevalence of diseases
The general incidence of women's health problems has risen considerably in recent decades as a result of numerous reasons, including technical advances in diagnostic technologies and improved awareness, which has led to the adoption of preventative care. Due to the notable increase in incidence, there is now a substantial patient population with chronic and crippling illnesses that have a negative impact on daily functioning and significantly increase the risk of death. These are the aspects affecting the market's expansion.
High maintenance and complexity
These gadgets require pricey routine upkeep and repairs. Higher expenses may result from the demand for specialized technicians or parts. There may be a period of inactivity when equipment needs to be serviced or maintained. This might affect arranged appointments or healthcare services. Some gadgets are difficult to maintain because they are complicated and sophisticated. Lengthier repair durations may also result from this complexity. As a result, this factor may prevent market growth.
The COVID-19 epidemic caused a reduction in income for major participants in the industry. During the pandemic, there was a decrease in the demand for female contraceptive goods, including ovulation monitors, intrauterine devices, menstrual pain management, and female condoms. Sales of female contraceptive devices fell as a result of consumer mobility constraints and stringent social distance rules that discouraged socializing.
The chronic diseases segment is expected to be the largest during the forecast period
The chronic diseases segment is expected to be the largest during the forecast period. The incidence of chronic illnesses, including diabetes, cancer, heart disease, and other conditions, is increasing among women due to dietary changes, physical inactivity, and altered lifestyles. The most common chronic illness affecting women is cancer. This sector has grown dramatically as a result of the increasing incidence of lung cancer, ovarian cancer, colon cancer, and breast cancer among women.
The hospitals & clinics segment is expected to have the highest CAGR during the forecast period
The hospitals & clinics segment is expected to have the highest CAGR during the forecast period. This may be attributed only to the population's growing inclination towards using hospitals for treatment of most illnesses. The main drivers of the segment's growth have been the increased use of both public and private hospitals, the growth of private clinics, the availability of specialized wards for women at hospitals, and the strength and development of the hospital's infrastructure for diagnosis and treatment.
North America is projected to hold the largest market share during the forecast period owing to the presence of huge female population in the region. High spending on women's health care and a correspondingly high demand for high-tech devices are expected to contribute to the region's dominance. It is anticipated that the leading market players in the area will continue to increase their spending in R&D, clinical studies, and the introduction of innovative health gadgets, which will further increase demand in the market.
Asia Pacific is projected to hold the highest CAGR over the forecast period. The increased government initiatives to promote gender equality in the nation have resulted in a surge in the women population. Moreover, the rising participation of women in the workforce is resulting in the increased disposable income of the women. The rising prevalence of various chronic diseases such as cancer, diabetes, cardiovascular diseases, and respiratory disorders among the women population is expected to augment the growth of the market.
Key players in the market
Some of the key players in Women's Health Devices market include Koninklijke Philips, Siemens AG, Prestige Consumer Healthcare, Inc., Caldera Medical, MedGyn Products, Medline Industries, Abbott Laboratories, Carestream Health, GE Healthcare, F. Hoffmann-La Roche, Hologic, CooperSurgical, Inc. , Innovative Health Diagnostic and BioSkryb Genomics.
In December 2022, CooperSurgical, Inc. partnered with Ostro to launch a new consumer engagement solution for CooperSurgical's hormone-free IUD, Paragard. Paragard is an FDA-approved intrauterine device that prevents pregnancy up to 10 years.
In October 2022, BioSkryb Genomics signed a multi-year agreement with Cooper Genomics to license BioSkryb's proprietary genomic amplification technology. Cooper Genomics will utilize BioSkryb technology to enhance its preimplantation genetic testing (PGT) capabilities.